Autocrine activation of the local insulin-like growth factor I system is up-regulated by estrogen receptor (ER)-independent estrogen actions and accounts for decreased ER expression in type 2 diabetic mesangial cells

Endocrinology

Volumn 146, Issue 2, 2005, Pages 889-900

  Karl, Michael ^a   Potier, Mylene ^a   Schulman, Ivonne H ^a   Rivera, Ana ^a   Werner, Haim ^b   Fornoni, Alessia ^a   Elliot, Sharon J ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ESTROGEN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; SOMATOMEDIN C;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOCRINE EFFECT; CARDIOVASCULAR RISK; CONTROLLED STUDY; ENZYME ACTIVATION; ESTROGEN ACTIVITY; FEMALE; GENETIC TRANSCRIPTION; GLOMERULOSCLEROSIS; HEART PROTECTION; HORMONAL REGULATION; MESANGIUM CELL; MOLECULAR INTERACTION; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; RISK ASSESSMENT; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; AUTOCRINE COMMUNICATION; BLOTTING, WESTERN; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGENS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GLOMERULAR MESANGIUM; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; MICE; MICE, INBRED C57BL; MICE, INBRED NOD; PHOSPHORYLATION; PROMOTER REGIONS (GENETICS); RECEPTOR, IGF TYPE 1; RNA, MESSENGER; TRANS-ACTIVATION (GENETICS); UP-REGULATION;

EID: 12344288180     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/en.2004-1121     Document Type: Article

References (59)

1. Parving H, Ritz E 2000 Diabetic nephropathy. In: Brenner B, Levine S, eds. The kidney. Philadelphia: Saunders; 1731
2. Osterby R, Gundersen HJG 1975 Glomerular size and structure in diabetes mellitus. Diabetologia 11:225-229
3. Steffes MW, Osterby R, Chavers B, Mauer SM 1989 Mesangial expansion as a central mechanism for loss of kidney function in diabetic patients. Diabetes 38:1077-1081
4. Lenz O, Elliot SJ, Stetler-Stevenson WG 2000 Matrix metalloproteinases in renal development and disease. J Am Soc Nephrol 11:574-581
5. Alric C, Pecher C, Cellier E, Schanstra JP, Poirier B, Chevalier J, Bascands JL, Girolami JP 2002 Inhibition of IGF-I-induced Erk 1 and 2 activation and mitogenesis in mesangial cells by bradykinin. Kidney Int 62:412-421
6. Elliot SJ, Striker LJ, Hattori M, Yang CW, He CJ, Peten EP, Striker GE 1993 Mesangial cells from diabetic NOD mice constitutively secrete increased amounts of insulin-like growth factor-I. Endocrinology 133:1783-1788
7. Werner H, Shen-Orr Z, Stannard B, Burguera B, Roberts Jr CT, LeRoith D 1990 Experimental diabetes increases insulinlike growth factor 1 and 11 receptor concentration and gene expression in kidney. Diabetes 39:1490-1497
8. Lupia E, Elliot SJ, Lenz O, Zheng F, Hattori M, Striker GE, Striker LJ 1999 IGF-I decreases collagen degradation in diabetic NOD mesangial cells: implications for diabetic nephropathy. Diabetes 48:1638-1644
9. Tack I, Elliot SJ, Potier M, Rivera A, Striker GE, Striker LJ 2002 Autocrine activation of the IGF-1 signaling pathway in mesangial cells isolated from diabetic NOD mice. Diabetes 51:182-188
10. Oemar BS, Foellmer HG, Hodgdon-Anandant L, Rosenzweig SA 1991 Regulation of insulin-like growth factor 1 receptors in diabetic mesangial cells. J Biol Chem 266:2369-2373
11. Sowers JR 1998 Diabetes mellitus and cardiovascular disease in women. Arch Intern Med 158:617-621
12. Kaseta JR, Skafar DF, Ram JL, Jacober SJ, Sowers JR 1999 Cardiovascular disease in the diabetic woman. J Clin Endocrinol Metab 84:1835-1838
13. Neugarten J, Acharya A, Silbiger S 2000 Effect of gender on the progression of nondiabetic renal disease: a meta-analysis. J Am Soc Nephrol 11:319-329
14. Skafar DF, Xu R, Morales J, Ram J, Sowers JR 1997 Female sex hormones and cardiovascular disease in women. J Clin Endocrinol Metab 82:3913-3918
15. Potier M, Elliot SJ, Tack I, Lenz O, Striker GE, Striker LJ, Karl M 2001 Expression and regulation of estrogen receptors in mesangial cells: influence on matrix metalloproteinase-9. J Am Soc Nephrol 12:241-251
16. Potier M, Karl M, Zheng F, Elliot SJ, Striker GE, Striker LJ 2002 Estrogen-related abnormalities in glomerulosclerosis-prone mice: reduced mesangial cell estrogen receptor expression and prosclerotic response to estrogens. Am J Pathol 160:1877-1885
17. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB 1998 Prediction of coronary heart disease using risk factor categories. Circulation 97:1837-1847
18. Booth G, Rothwell D, Fung D-W, Tu J 2003 The impact of age on cardiovascular risk associated with diabetes. Endocrinologist 13:S3
19. Crook ED, Harris J, Oliver B, Fleischman E, Crenshaw G, Taylor R 2001 Endstage renal disease owing to diabetic nephropathy in Mississippi: an examination of factors influencing renal survival in a population prone to late referral. J Invest Med 49:284-291
20. U.S. Renal Data System 2000 USRDS 2000 Annual data report. 2nd ed. Bethesda, MD: NIH, NIDDK
21. Purdy LP, Hantsch CE, Molitch ME, Metzger BE, Phelps RL, Dooley SL, Hou SH 1996 Effect of pregnancy on renal function in patients with moderate-to-severe diabetic renal insufficiency. Diabetes Care 19:1067-1074
22. Stoica A, Saceda M, Fakhro A, Joyner M, Martin MB 2000 Role of insulin-like growth factor-I in regulating estrogen receptor-α gene expression. J Cell Biochem 76:605-614
23. Cardona-Gomez GP, Mendez P, DonCarlos LL, Azcoitia I, Garcia-Segura LM 2002 Interactions of estrogen and insulin-like growth factor-I in the brain: molecular mechanisms and functional implications. J Steroid Biochem Mol Biol 83:211-217
24. Hamelers IH, Steenbergh PH 2003 Interactions between estrogen and insulin-like growth factor signaling pathways in human breast tumor cells. Endocr Relat Cancer 10:331-345
25. Kahlert S, Nuedling S, van Eickels M, Vetter H, Meyer R, Grohe C 2000 Estrogen receptor α rapidly activates the IGF-1 receptor pathway. J Biol Chem 275:18447-18453
26. Klotz DM, Hewitt SC, Ciana P, Raviscioni M, Lindzey JK, Foley J, Maggi A, DiAugustine RP, Korach KS 2002 Requirement of estrogen receptor-α in insulin-like growth factor-1 (IGF-1)-induced uterine responses and in vivo evidence for IGF-1/estrogen receptor cross-talk. J Biol Chem 277:8531-8537
27. Lou H, Ramwell PW, Foegh ML 1998 Estradiol 17-β represses insulin-like growth factor I receptor expression in smooth muscle cells from rabbit cardiac recipients. Transplantation 66:419-426
28. Scheidegger KJ, Cenni B, Picard D, Delafontaine P 2000 Estradiol decreases IGF-I and IGF-I receptor expression in rat aortic smooth muscle cells: mechanisms for its atheroprotective effects. J Biol Chem 275:38921-38928
29. Chen S, Carmen Iglesias-de la Cruz, Jim B, Hong SW, Isono M, Ziyadeh FN 2003 Reversibility of established diabetic glomerulopathy by anti-TGF-β antibodies in db/db mice. Biochem Biophys Res Commun 300:16-22
30. Wolf G, Ziyadeh FN 1999 Molecular mechanisms of diabetic renal hypertrophy. Kidney Int 56:393-405
31. Chen H, Charlat O, Tartaglia LA, Woolf EA, Weng X, Ellis SJ, Lakey ND, Culpepper J, Moore KJ, Breitbart RE, Duyk GM, Tepper RI, Morgenstern JP 1996 Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell 84:491-495
32. Hummel KP, Coleman DL, Lane PW 1972 The influence of genetic background on expression of mutations at the diabetes locus in the mouse. 1. C57BL-KsJ and C57BL-6J strains. Biochem Genet 7:1-13
33. Schulman I, Zheng F, Plati A, Zisman A, Potier M, Elliot SJ, Leclercq B, Striker, GE, Striker LJ, The C57BL/6J db/db mouse as a model of diabetic glomerulosclerosis in normotensive, obese type 2 diabetic subjects. Journal of the American Society of Nephrology Annual Meeting, Philadelphia, PA, 2002, p 537 A (Abstract)
34. Sharma K, McCue P, Dunn SR 2003 Diabetic kidney disease in the db/db mouse. Am J Physiol 284:F1138-F1144
35. Werner H, Rauscher III FJ, Sukhabne VP, Drummond IA, Roberts Jr CT, LeRoith D 1994 Transcriptional repression of the insulin-like growth factor I receptor (IGF-I-R)gene by the tumor suppressor WT1 involves binding to sequences both upstream and downstream of the IGF-I-R gene transcription start site. J Biol Chem 269:12577-12582
36. Horney MJ, Shirley DW, Kurtz DT, Rosenzweig SA 1998 Elevated glucose increases mesangial cell sensitivity to insulin-like growth factor I. Am J Physiol 274:F1045-F1053
37. Firth SM, Baxter RC 2002 Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 23:824-854
38. Lee AV, Jackson JG, Gooch JL, Hilsenbeck SG, Coronado-Heinsohn E, Osborne CK, Yee D 1999 Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol Endocrinol 13:787-796
39. Richards RG, Walker MP, Sebastian J, DiAugustine RP 1998 Insulin-like growth factor-1 (IGF-1) receptor-insulin receptor substrate complexes in the uterus. Altered signaling response to estradiol in the IGF-1(m/m) mouse. J Biol Chem 273:11962-11969
40. LeRoith D 2000 Insulin-like growth factor I receptor signaling- overlapping or redundant pathways? Endocrinology 141:1287-1288
41. Neugarten J, Medve I, Lei J, Silbiger SR 1999 Estradiol suppresses mesangial cell type 1 collagen synthesis via activation of the MAP kinase cascade. Am J Physiol 277:F875-F881
42. Oh AS, Lorant LA, Holloway JN, Miller DL, Kern FG, El Ashry D 2001 Hyperactivation of MAPK induces loss of ERα expression in breast cancer cells. Mol Endocrinol 15:1344-1359
43. Fornoni A, Elliot SJ, Rosenzweig SA, Rivera A, Lenz O, Striker LJ, Striker GE, Low IGFBP-2 expression is responsible for increased IGF-1 pathway activation in mesangial cells from glomerulosclerosis prone ROP mice. Journal of the American Society of Nephrology Annual Meeting, Philadelphia, PA, 2003, p 127A (Abstract)
44. Rosenzweig SA 2004 What's new in the IGF-binding proteins? Growth Horm IGF Res 14:329-336
45. Flyvbjerg A 2000 Putative pathophysiological role of growth factors and cytokines in experimental diabetic kidney disease. Diabetologia 43:1205-1223
46. Bjomstrom L, Sjoberg M 2002 Signal transducers and activators of transcription as downstream targets of nongenomic estrogen receptor actions. Mol Endocrinol 16:2202-2214
47. Coleman KM, Smith CL 2001 Intracellular signaling pathways: nongenomic actions of estrogens and ligand-independent activation of estrogen receptors. Front Biosci 6:D1379-D1391
48. Behl C, Skutella T, Lezoualc'h F, Post A, Widmann M, Newton CJ, Holsboer F 1997 Neuroprotection against oxidative stress by estrogens: structure-activity relationship. Mol Pharmacol 51:535-541
49. Diaz-Perez MJ, Zannis-Hadjopoulos M, Price GB, Wainer IW 1998 Receptor independent effects on DNA replication by steroids. J Cell Biochem 70:323-329
50. Singh M, Setalo Jr G, Guan X, Frail DE, Toran-Allerand CD 2000 Estrogen-induced activation of the mitogen-activated protein kinase cascade in the cerebral cortex of estrogen receptor-α knock-out mice. J Neurosci 20:1694-1700
51. Levin ER 2002 Cellular functions of plasma membrane estrogen receptors. Steroids 67:471-475
52. Lu Q, Ebling H, Mittler J, Baur WE, Karas RH 2002 MAP kinase mediates growth factor-induced nuclear translocation of estrogen receptor α. FEBS Lett 516:1-8
53. Razandi M, Pedram A, Park ST, Levin ER 2003 Proximal events in signaling by plasma membrane estrogen receptors. J Biol Chem 278:2701-2712
54. Speir E, Yu ZX, Takeda K, Ferrans VJ, Cannon III RO 2000 Antioxidant effect of estrogen on cytomegalovirus-induced gene expression in coronary artery smooth muscle cells. Circulation 102:2990-2996
55. Prokai L, Prokai-Tatrai K, Perjesi P, Zharikova AD, Ferez EJ, Liu R, Simpkins JW 2003 Quinol-based cyclic antioxidant mechanism in estrogen neuroprotection. Proc Natl Acad Sci USA 100:11741-11746
56. Wakeling AE, Dukes M, Bowler J 1991 A potent specific pure antiestrogen with clinical potential. Cancer Res 51:3867-3873
57. Frasor J, Stossi F, Danes JM, Komm B, Lyttle CR, Katzenellenbogen BS 2004 Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells. Cancer Res 64:1522-1533
58. Santen RJ, Song RX, McPherson R, Kumar R, Adam L, Jeng MH, Yue W 2002 The role of mitogen-activated protein (MAP) kinase in breast cancer. J Steroid Biochem Mol Biol 80:239-256
59. Kim-Schulze S, Lowe Jr WL, Schnaper HW 1998 Estrogen stimulates delayed mitogen-activated protein kinase activity in human endothelial cells via an autocrine loop that involves basic fibroblast growth factor. Circulation 98:413-421